9 Meters Biopharma Book Value 2011-2026 | NMTR

Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.

What is included in book value

Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.

Features of the metric

Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account.
Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market.
Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors.
Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.

Annual Book Value 9 Meters Biopharma

2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
2.4 M	41.6 M	32.1 M	-9.61 M	-3.66 M	-1.97 M	2.49 M	-5.69 M	-4.99 M	-536 K	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
41.6 M	-9.61 M	5.22 M

Quarterly Book Value 9 Meters Biopharma

2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-6.3 M	2.4 M	13.5 M	22.1 M	30.9 M	41.6 M	49.3 M	59.1 M	34.1 M	32.1 M	32.1 M	32.1 M	32.1 M	-9.61 M	-9.61 M	-4.34 M	-5.68 M	-3.66 M	6.45 M	6.45 M	-3.66 M	798 K	798 K	798 K	798 K	6.46 M	6.46 M	6.46 M	6.46 M	4.72 M	4.72 M	4.72 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
59.1 M	-9.61 M	12.3 M

Book Value of other stocks in the Biotechnology industry

Issuer	Book Value	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	49 M	-	2.43 %	$ 254 M	Germany
AgeX Therapeutics AGE	-37 K	-	-10.17 %	$ 12.2 K	USA
I-Mab IMAB	5.63 B	-	-	$ 866 M	China
Akero Therapeutics AKRO	750 M	-	-	$ 3.67 B	USA
Midatech Pharma plc MTP	11.4 M	-	-18.52 %	$ 27.3 M	Britain
AlloVir ALVR	78.8 M	-	4.14 %	$ 49.1 M	USA
Alexion Pharmaceuticals, Inc. ALXN	253 M	-	-	$ 40.3 B	USA
Aptorum Group Limited APM	13.8 M	$ 0.88	-1.69 %	$ 6.47 M	China
Biophytis SA BPTS	34.9 M	-	-13.47 %	$ 169 M	France
Genfit SA GNFT	282 M	-	2.54 %	$ 160 B	France
Aquestive Therapeutics AQST	-33.7 M	$ 4.1	1.23 %	$ 438 M	USA
ACADIA Pharmaceuticals ACAD	733 M	$ 22.45	1.13 %	$ 3.72 B	USA
EyeGate Pharmaceuticals, Inc. EYEG	2.33 B	-	-1.52 %	$ 24.7 M	USA
Athira Pharma ATHA	27.8 M	-	-	$ 269 M	USA
Applied Molecular Transport AMTI	60.8 M	-	-	$ 10.1 M	USA
Ayala Pharmaceuticals AYLA	7.77 M	-	-	$ 7.46 M	Israel
AstraZeneca PLC AZN	48.7 B	-	-	$ 96.9 B	Britain
Atreca BCEL	78.4 M	-	-11.76 %	$ 5.79 M	USA
Berkeley Lights BLI	142 M	-	-7.31 %	$ 87 M	USA
Calithera Biosciences CALA	49.1 M	-	-10.95 %	$ 876 K	USA
Advaxis ADXS	16.6 M	-	-9.65 %	$ 45.9 M	USA
CymaBay Therapeutics CBAY	292 M	-	-	$ 3.45 B	USA
ChemoCentryx CCXI	286 M	-	-	$ 3.74 B	USA
Cerus Corporation CERS	65 M	$ 2.03	5.73 %	$ 387 M	USA
Институт стволовых клеток человека ISKJ	10.6 M	-	-	-	Russia
Caladrius Biosciences CLBS	29.3 M	-	-16.75 %	$ 25.8 M	USA
Checkmate Pharmaceuticals CMPI	69.5 M	-	-	$ 231 M	USA
Kazia Therapeutics Limited KZIA	18.6 M	$ 13.64	9.82 %	$ 1.81 B	Australia
Aeterna Zentaris AEZS	3.84 M	-	5.93 %	$ 314 M	Canada
BioNTech SE BNTX	19.2 B	$ 103.45	1.85 %	$ 27.2 B	Germany
Brainstorm Cell Therapeutics BCLI	-9.98 M	-	-2.5 %	$ 5.88 M	USA
Aeglea BioTherapeutics AGLE	715 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	29.5 M	-	-	$ 26.5 M	USA
Deciphera Pharmaceuticals DCPH	351 M	-	-	$ 2.18 B	USA
AIkido Pharma AIKI	69.4 M	-	1.93 %	$ 17.4 M	USA
Innate Pharma S.A. IPHA	267 M	$ 1.44	-3.36 %	$ 235 M	France
Dynavax Technologies Corporation DVAX	597 M	-	-	$ 2.02 B	USA
Akouos AKUS	234 M	-	0.23 %	$ 488 M	USA
Allakos ALLK	169 M	-	-	$ 28.6 M	USA
Editas Medicine EDIT	27.3 M	$ 3.0	6.38 %	$ 266 M	USA
Edesa Biotech EDSA	1.98 M	$ 18.27	14.94 %	$ 58.4 M	USA
Can-Fite BioPharma Ltd. CANF	20.3 M	$ 3.19	6.69 %	$ 5.25 M	Israel
Eiger BioPharmaceuticals EIGR	-14.5 M	-	-9.21 %	$ 2.55 M	USA
Eloxx Pharmaceuticals ELOX	-10.7 M	-	-5.68 %	$ 8.28 M	USA
CureVac N.V. CVAC	688 M	-	-	$ 867 M	Germany
Ampio Pharmaceuticals AMPE	3.36 M	-	-11.43 %	$ 502 K	USA
Applied Therapeutics APLT	-17.1 M	-	-	$ 8.42 M	USA
Aptose Biosciences APTO	-27.2 M	-	-45.71 %	$ 1.2 M	Canada
Aptinyx APTX	38.3 M	-	-39.0 %	$ 4.57 M	USA
Aravive ARAV	10.7 M	-	-13.39 %	$ 1.45 M	USA